{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae HSV-1 Type Specific IgG",
        "LIAISON\u00ae Control HSV-1 IgG"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K081685",
    "Predicate Device Reference 510(k) Number(s)": [
        "K000238"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXJ",
        "JJX"
    ],
    "Summary Letter Date": "November 18, 2008",
    "Summary Letter Received Date": "October 10, 2008",
    "Submission Date": "October 9, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.3305"
    ],
    "Regulation Name(s)": [
        "Herpes Simplex Virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "HSV-1 IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect immunoassay"
    ],
    "Methodologies": [
        "Serological qualitative detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON\u00ae HSV-1 Type Specific IgG assay and controls for qualitative detection of HSV-1 IgG antibodies in human serum using chemiluminescent immunoassay with the LIAISON\u00ae Analyzer",
    "Indications for Use Summary": "Qualitative determination of type specific IgG antibodies to HSV-1 in human serum from sexually active adults or expectant mothers to aid in the presumptive diagnosis of HSV-1 infection; not for pediatric, neonatal, immunocompromised patients, or blood/plasma donor screening",
    "fda_folder": "Microbiology"
}